Tandutinib Completed Phase 2 Trials for Metastatic Cancers / Pain / Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00390468Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases